PEGylated therapeutics in the clinic
Bioengineering & Translational Medicine · 2024-01 · 9 (1)
DOI: 10.1002/btm2.10600 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 22.09.2023. Verfasst von Yongsheng Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: John A. Paulson School of Engineering and Applied Sciences, Harvard University Allston Massachusetts USA. Die Arbeit wurde bisher 248-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Harvard School of Engineering and Applied Sciences, National Institutes of Health.
Abstract (Originalsprache)
The covalent attachment of polyethylene glycol (PEG) to therapeutic agents, termed PEGylation, is a well‐established and clinically proven drug delivery approach to improve the pharmacokinetics and pharmacodynamics of drugs. Specifically, PEGylation can improve the parent drug's solubility, extend its circulation time, and reduce its immunogenicity, with minimal undesirable properties. PEGylation technology has been applied to various therapeutic modalities including small molecules, aptamers, peptides, and proteins, leading to over 30 PEGylated drugs currently used in the clinic and many investigational PEGylated agents under clinical trials. Here, we summarize the diverse types of PEGylation strategies, the key advantages of PEGylated therapeutics over their parent drugs, and the broad applications and impacts of PEGylation in clinical settings. A particular focus has been given to the size, topology, and functionalities of PEG molecules utilized in clinically used PEGylated drugs, as well as those under clinical trials. An additional section has been dedicated to analyzing some representative PEGylated drugs that were discontinued at different stages of clinical studies. Finally, we critically discuss the current challenges faced in the development and clinical translation of PEGylated agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- John A. Paulson School of Engineering and Applied Sciences, Harvard University Allston Massachusetts USA.
- Wyss Institute for Biologically Inspired Engineering at Harvard University Boston Massachusetts USA.
- Present address: Department of Bioengineering The University of Texas at Dallas Richardson TX USA.
- Department of Pharmaceutical Sciences College of Pharmacy, University of Illinois at Chicago Chicago Illinois USA.
ORCID-Profile: Yongsheng Gao, Maithili Joshi, Zongmin Zhao, Samir Mitragotri
Förderung
- NIGMS NIH HHS
- Harvard School of Engineering and Applied Sciences
- National Institutes of Health
Zitieren
APA
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024). PEGylated therapeutics in the clinic. Bioengineering & Translational Medicine, 9(1). https://doi.org/10.1002/btm2.10600
Vancouver
Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioengineering & Translational Medicine. 2024;9(1). doi:10.1002/btm2.10600
BibTeX
@article{Gao2024,
author = {Gao, Yongsheng and Joshi, Maithili and Zhao, Zongmin and Mitragotri, Samir},
title = {PEGylated therapeutics in the clinic},
journal = {Bioengineering & Translational Medicine},
year = {2024},
volume = {9},
number = {1},
doi = {10.1002/btm2.10600}
}
EUVIMED